ELCC 2019: Larotrectinib in TRK Fusion–Positive Lung Cancer
Posted: Thursday, April 25, 2019
According to a subset data analysis from the LOXO-TRK-14001 and NAVIGATE trials, larotrectinib appears to be active in some patients with non–small cell lung cancer (NSCLC). These findings, presented by Alexander Drilon, MD, of the Memorial Sloan Kettering Cancer Center, and colleagues at the 2019 European Lung Cancer Congress (ELCC) in Geneva (Abstract 111O), support “routine molecular testing” for patients with lung cancer. The tropomyosin receptor kinase (TRK) inhibitor was approved in late 2018 for the treatment of adult and pediatric patients with TRK fusion–positive solid tumors.
In this study, the data of 11 patients with metastatic, TRK fusion–positive NSCLC were culled from the phase I LOXO-TRK-14001 trial and the phase II NAVIGATE trial. Eight patients had fusions involving NTRK1 and diverse fusion partners, and three patients had fusions involving NTRK3 and diverse fusion partners. Ten patients had received prior systemic therapy.
Of the 11 patients included, 7 patients were evaluable for response to larotrectinib. The median time to response was 1.8 months, and the overall response rate was 71%; 1 patient achieved a complete response, 4 had a partial response, and 2 had stable disease. The median duration of response was not yet reached, and treatment-related adverse events were mostly limited to grade 1 and grade 2.
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.
